1. Home
  2. KPTI vs ENTX Comparison

KPTI vs ENTX Comparison

Compare KPTI & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • ENTX
  • Stock Information
  • Founded
  • KPTI 2008
  • ENTX 2010
  • Country
  • KPTI United States
  • ENTX Israel
  • Employees
  • KPTI N/A
  • ENTX N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • KPTI Health Care
  • ENTX Health Care
  • Exchange
  • KPTI Nasdaq
  • ENTX Nasdaq
  • Market Cap
  • KPTI 44.5M
  • ENTX 104.0M
  • IPO Year
  • KPTI 2013
  • ENTX 2018
  • Fundamental
  • Price
  • KPTI $4.39
  • ENTX N/A
  • Analyst Decision
  • KPTI Buy
  • ENTX Strong Buy
  • Analyst Count
  • KPTI 6
  • ENTX 1
  • Target Price
  • KPTI $48.50
  • ENTX $10.00
  • AVG Volume (30 Days)
  • KPTI 53.3K
  • ENTX 33.0K
  • Earning Date
  • KPTI 08-05-2025
  • ENTX 08-08-2025
  • Dividend Yield
  • KPTI N/A
  • ENTX N/A
  • EPS Growth
  • KPTI N/A
  • ENTX N/A
  • EPS
  • KPTI N/A
  • ENTX N/A
  • Revenue
  • KPTI $142,126,000.00
  • ENTX $223,000.00
  • Revenue This Year
  • KPTI $2.09
  • ENTX N/A
  • Revenue Next Year
  • KPTI $12.90
  • ENTX N/A
  • P/E Ratio
  • KPTI N/A
  • ENTX N/A
  • Revenue Growth
  • KPTI 1.19
  • ENTX N/A
  • 52 Week Low
  • KPTI $3.51
  • ENTX $1.41
  • 52 Week High
  • KPTI $16.95
  • ENTX $2.79
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 45.76
  • ENTX 43.51
  • Support Level
  • KPTI $4.12
  • ENTX $1.84
  • Resistance Level
  • KPTI $4.85
  • ENTX $2.02
  • Average True Range (ATR)
  • KPTI 0.31
  • ENTX 0.14
  • MACD
  • KPTI 0.04
  • ENTX -0.01
  • Stochastic Oscillator
  • KPTI 36.99
  • ENTX 14.71

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Share on Social Networks: